European Journal of Heart Failure

Article	Citations
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices	1510
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?	205
Striving for the ‘perfect’ definition of iron deficiency in heart failure	138
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	134
	129
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail	117
Heart failure: age is no excuse for complacency	116
Dissecting the heart failure phenotype through phenomics	115
Issue Information	106
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	102
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival	101
Abstract	101
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES	99
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials	94
Abstract	91
Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of ‘too little, too late’	89
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials	76
Issue Information	72
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology	71
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h	70
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up	65
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management	65
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	62
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure	62
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF	61

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	60
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	60
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	59
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial	59
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock	57
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices	56
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians	56
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato	55
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	55
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction	54
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial	53
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases	53
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold	53
Issue Information	52
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery	52
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial	52
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities	52
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE	52
Issue Information	51
	51
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	51
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models	51
Corrigendum to ‘Congestion in heart failure: A circulating biomarker‐based perspective’ and articles listed below	50
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’	50
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	50
Serial direct sodium removal in patients with heart failure and diuretic resistance	50
Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction	49
Health status across major subgroups of patients with heart failure and preserved ejection fraction	49
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study	49
Heart failure improvement, remission, and recovery: A European Journal of Heart Failure expert consensus document	49
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation	49
Letter regarding the article ‘Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and	48
Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis	48
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	48
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions	47
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis	46
Predicting survival in patients with severe heart failure: Risk score validation in the HELP‐HF cohort	46
Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction	46
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	45
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors	45
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	45
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure	44
Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study	44
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary	44
The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis	44
The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial	44
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research	44
Remote patient management of heart failure across the ejection fraction spectrum: A pre‐specified analysis of the TIM‐HF2 trial	44
Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock	43
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy	43

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced	42
The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial	41
Use of mechanical circulatory support in patients with non‐ischaemic cardiogenic shock	41
	40
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	40
Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes	40
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future	40
	39
Reply to the letter regarding the article ‘Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines’	39
The impact of early surgery on mortality in infective endocarditis complicated by heart failure – How much more data do we need?	39
	39
Issue Information	38
Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?	38
Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article ‘Artificial intelligence and heart failure: A state‐of‐the‐art review’	38
Predicting heart failure: The promise of proteomics	37
Clinical trials: conventional or pragmatic?	37
Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors – Insights from the ACTION‐MEMS study	37
Supplement Article	37
No longer from pillar to post: The first effective step in treating heart failure with preserved ejection fraction	37
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	36
More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!	36
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation	36
Biventricular cardiac power reserve in heart failure with preserved ejection fraction	36
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	36
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis	36
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan	35
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry	35
Comparison of pulmonary congestion severity using artificial intelligence‐assisted scoring versus clinical experts: A secondary analysis of BLUSHED‐AHF	35
Corrigendum to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction”	35
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data	35
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved	35
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	34
Decreased left ventricular ejection fraction is associated with increased mortality in sepsis: A retrospective cohort study	34
Reply to ‘Is sodium chloride supplementation ready for clinical practice in acute heart failure?’	34
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudina	33
Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy	33
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial	33
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	33
Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial	33
The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry	33
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?	33
Disproportionate exercise‐induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non‐invasive echocardiographic study	33
Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC)	33
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial	33
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	33
Revolutionizing cardiogenic shock treatment: Is the microaxial flow pump the ultimate game changer?	33
Letter regarding the article ‘Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction’	32
Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the Car	32
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria	32
Video thermography uncovers relationship between volume status and temperature in heart failure	32
Late diagnosis in cancer sparks outrage—so why not heart failure?	32
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction	32
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study	32
Issue Information	31
Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end‐stage heart failure	31
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC	31
Reply to the letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’	31
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF	31
The heart during iron deficiency: a non‐rechargeable battery?	31
Trends in heart failure mortality in Sweden between 1997 and 2022	31
Assessing health status after discharge for decompensated heart failure: a patient‐centred priority	30
Issue Information	30
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Associatio	30
Recovery of cardiac function following COVID‐19	30
Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO‐HF trial	30
Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney	30
Arrhythmic risk management after acute myocarditis: never too early, only too late	30
Cardiac reverse remodelling with vericiguat: Victory or no victory?	30
Transcatheter edge‐to‐edge repair: fix the heart, heal the liver	30
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency	30
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial	29
Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy	29
	29
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta	29
Issue Information	29
Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum	29
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure	29
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF	29
Correction to ‘What's new in heart failure? May–June 2024’, ‘What's new in heart failure? June–July 2024’, ‘What's new in heart failure? August–September 2024’, ‘The month in heart failure! September	29
The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal	28

Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE‐	28
Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program	28
Myocardial perfusion in cardiac amyloidosis	28
Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial	28
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis	27
Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure	27
Reply to the letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’	27
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial	27
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER	27
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of	27
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction	27
End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)	27
Early changes in renal function during rapid up‐titration of guideline‐directed medical therapy following an admission for acute heart failure	26
Measures of left atrial function predict incident heart failure in a low‐risk general population: the Copenhagen City Heart Study	26
Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial	26
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	26
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases	26
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial	26
Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction	26
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry‐based analysis	26
Improve heart function to improve heart failure outcomes: the disease‐modifying effects of spironolactone	25
Prioritizing prevention of de novo and worsening chronic heart failure	25
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy	25
Transthyretin amyloidosis: the picture is getting clearer	25
Reply to the letter regarding the article ‘Acute heart failure after non‐cardiac surgery: incidence, phenotypes, determinants and outcomes’	25
Corrigendum to ‘Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials’ [Eur J Heart Fail 2016;18:684–692]	25
When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure	25
Reply to ‘Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in subjects with heart failure?’ Letter regarding the article ‘Impact o	25
Corrigendum to ‘Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction’ [Eur J Heart Fail 2021; 23: 983–991]	25
Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction	24
Bug attack! The rising importance of Chagas disease	24
Early and short‐term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD‐HF)	24
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the	24
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis’	24
Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals	24
Implementing the evidence – the true summit of evidence‐based care and the false peak of guidelines	24
Letter regarding the article ‘Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with th	24
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	24
Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out…?!	24
Growth differentiation factor‐15: A promising biomarker for early detection of pre‐heart failure	23
The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management	23
Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind	23
Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation	23
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis	23
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease	23
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?	23
A second wind for digitalis glycosides in heart failure?	23
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	23
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	23
If a patient does not require treatment with loop diuretics, do they really have heart failure?	23
Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows	22
Sodium chloride supplementation in acute heart failure: A closer look at SOLVRED‐AHF. Letter regarding the article ‘Sodium chloride versus glucose solute as a volume replacement	22
Changes in natriuretic peptide levels following patiromer‐enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study	22
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure – mechanism of action (SPONGE‐HF)	22
Time to treat the climate and nature crisis as one indivisible global health emergency	22
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial	22
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge‐to‐edge repair – Results from the TriValve	22
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61	22
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta‐analysis	22
Peri‐procedural management of transcatheter mitral valve replacement in patients with heart failure	21
Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension	21
Functional mitral regurgitation: a proportionate or disproportionate focus of attention?	21
Issue Information	21
Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction	21
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	21
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left‐sided valvular heart disease in Europe. Insights from the ESC‐EORP Valvular	21
	21
A Heart Team approach to contemporary device decision‐making in heart failure	21
Worsening heart failure comes into focus, chronic heart failure takes a backseat	21
Time to reconsider the perception and management of hypertensive heart disease	21
Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes	21
Reply to: ‘What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?’	21
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm A	21
Giant cell myocarditis after first dose of BNT162b2 – a case report	20
Kidney involvement in transthyretin cardiac amyloidosis – Role of urinary albumin to creatinine ratio and need for further evidence generation	20
The pharmacist ally in heart failure: Useful when involved. Letter regarding the article ‘Effective medications can work only in patients who take them: Implications for post‐acute heart failure care’	20
Heart failure related central sympathetic activation: debunking the ‘holy grail’?	20
Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines	20
Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure? Letter regarding the article ‘Impact of epicardia	20
	20
	20
Effect of phosphodiesterase‐5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double‐blind, randomized, placebo‐controlled trial: SERVE	20
An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum	20
A machine‐learning‐based prediction model in patients with takotsubo syndrome: ‘You can't stop change any more than you can stop the suns from setting!’	20
Time for differential weight management in heart failure	19
In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial	19
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock	19
Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides	19
Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology	19
Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry	19
Persistent high mortality in acute myocardial infarction‐associated cardiogenic shock despite early mechanical circulatory support: Need for stepwise and integrated approach of care	19
Supplement Article	19
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study	19
Predicting survival after Impella implantation in patients with cardiogenic shock: The J‐PVAD risk score	19
Residual tricuspid regurgitation after tricuspid transcatheter edge‐to‐edge repair: Insights into the EuroTR registry	19